Spots Global Cancer Trial Database for rhabdomyosarcoma
Every month we try and update this database with for rhabdomyosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors | NCT01661400 | Glioma Neuroectodermal... Wilms Tumor Rhabdomyosarcom... Sarcoma, Ewing Osteosarcoma Retinoblastoma | Metronomic Cycl... Thalidomide | 6 Months - 21 Years | Washington University School of Medicine | |
| Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients | NCT03462888 | Rhabdomyosarcom... | 15 Years - 25 Years | Centre Oscar Lambret | ||
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | NCT01674101 | Osteosarcoma Ewing's Sarcoma Rhabdomyosarcom... Synovial Sarcom... Malignant Perip... Malignant Fibro... Chondrosarcoma ... | Endurance Strengthening Stretching Home exercise p... | 6 Years - 30 Years | St. Jude Children's Research Hospital | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Trial of Afatinib in Pediatric Tumours | NCT02372006 | Neuroectodermal... Rhabdomyosarcom... | afatinib | 1 Year - 18 Years | Boehringer Ingelheim | |
| New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | NCT00001335 | Ewing's Sarcoma Neuroblastoma Rhabdomyosarcom... | ADR-529 Topotecan G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | NCT00043979 | Sarcoma | F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo... | 5 Years - 35 Years | National Institutes of Health Clinical Center (CC) | |
| Proton RT for the Treatment of Pediatric Rhabdomyosarcoma | NCT00592592 | Rhabdomyosarcom... | Proton Beam Rad... | - 21 Years | Massachusetts General Hospital | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800 | Medulloblastoma Rhabdomyosarcom... Neuroblastoma Hepatoblastoma Glioma Astrocytoma | LDE225 | 12 Months - 18 Years | Novartis | |
| Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | NCT05210374 | Relapsed Sarcom... | Disulfiram Copper Gluconat... Liposomal Doxor... | 1 Year - | Case Comprehensive Cancer Center | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| HGS-ETR2 to Treat Children With Solid Tumors | NCT00428272 | Ewing's Sarcoma Osteosarcoma Neuroblastoma Rhabdomyosarcom... | Lexatumumab alo... Lexatumumab in ... Interferon gamm... Gamma 1b potent... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | NCT01336803 | Bone Cancer Chondrosarcoma Ewing's Sarcoma Osteosarcoma Rhabdomyosarcom... Bone Necrosis Bone Sarcoma Osteomyelitis | Feraheme Magnetic Resona... | 10 Years - 21 Years | Stanford University | |
| A Vaccine Study for High Risk Cancers | NCT00944580 | Neuroblastoma Rhabdomyosarcom... Osteogenic Sarc... | MAGE-A1, MAGE-A... | 1 Year - 70 Years | Penn State University | |
| Impact of an Orthotic Intervention in Children With Peripheral Neuropathy | NCT03655587 | Gait, Drop Foot Chemotherapy-in... Acute Lymphocyt... Rhabdomyosarcom... Wilms Tumor | Solid ankle foo... Resting night s... | 5 Years - 14 Years | Children's Hospitals and Clinics of Minnesota | |
| Radiation Therapy to Treat Musculoskeletal Tumors | NCT00186992 | Sarcoma, Ewing'... Rhabdomyosarcom... Soft Tissue Sar... Musculoskeletal... | image-guided ra... | - 25 Years | St. Jude Children's Research Hospital | |
| Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials | NCT06029465 | Rhabdomyosarcom... | 18 Years - | Power Life Sciences Inc. | ||
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | NCT02536183 | Pediatric Cance... Solid Tumors Rhabdomyosarcom... Ewing Sarcoma Soft Tissue Sar... Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor... | Magnetic resona... Lyso-thermosens... | - 30 Years | Children's National Research Institute | |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | NCT02581384 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Osteosarcoma Non-Rhabdomyosa... Renal Tumor Rhabdoid Tumor Clear Cell Rena... Sarcoma Sarcoma, Ewing Soft Tissue Sar... | Stereotactic Bo... | - 21 Years | Dana-Farber Cancer Institute | |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | NCT02013336 | Recurrent or Re... Ewing Sarcoma Rhabdomyosarcom... Neuroblastoma Osteosarcoma | MM-398 (Irinote... | 12 Months - 20 Years | South Plains Oncology Consortium | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | NCT01241162 | Neuroblastoma Ewings Sarcoma Osteogenic Sarc... Rhabdomyosarcom... Synovial Sarcom... | Autologous dend... | 1 Year - 24 Years | University of Louisville | |
| PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine | NCT05697198 | Lung Cancer Ovarian Cancer Uterine Cancer Colorectal Canc... Stomach Cancer Esophageal Canc... Pancreatic Canc... Melanoma Breast Cancer Head and Neck C... Soft Tissue Sar... Rhabdomyosarcom... Prostate Cancer | OmniSeq Test | 18 Years - | Labcorp Corporation of America Holdings, Inc | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | NCT02076906 | Relapsed Pediat... Refractory Pedi... Rhabdomyosarcom... Ewing Sarcoma Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor Desmoid Tumor | Magnetic Resona... | - 30 Years | Children's National Research Institute | |
| Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma | NCT05457829 | Rhabdomyosarcom... | Doxorubicin Hyd... Temozolomide+Ir... | 6 Months - 18 Years | Sun Yat-sen University | |
| TAA-Specific CTLS for Solid Tumors (TACTASOM) | NCT02239861 | Rhabdomyosarcom... | TAA-Specific CT... | 2 Years - 80 Years | Baylor College of Medicine | |
| A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | NCT02509598 | Rhabdomyosarcom... Melanoma | Tc99m tilmanoce... Vital Blue Dye ... Lymph Node Mapp... | - 17 Years | Cardinal Health 414, LLC | |
| Molecular-Guided Therapy for Childhood Cancer | NCT02162732 | Neuroblastoma Medulloblastoma Glioma Ependymoma Choroid Plexus ... Craniopharyngio... Dysembryoplasti... Meningioma Primitive Neuro... Germ Cell Tumor... Rhabdomyosarcom... Non-rhabdomyosa... Ewings Sarcoma Osteosarcoma Wilms Tumor Renal Cell Carc... Malignant Rhabd... Clear Cell Sarc... Liver Tumors | Guided Therapy | 13 Months - 21 Years | Milton S. Hershey Medical Center | |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | NCT01625351 | Ewing Sarcoma Gastrointestina... Germ Cell Tumor Hepatic Tumor Lymphoma Wilms Tumor Rhabdoid Tumor Clear Cell Carc... Renal Cell Carc... Melanoma Neuroblastoma Rhabdomyosarcom... Non-rhabdomyosa... | alemtuzumab fludarabine sirolimus Busulfan melphalan stem cells CliniMACS | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | NCT00949325 | Sarcoma | temsirolimus pl... | 1 Year - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Molecular Analysis Of Solid Tumors | NCT01050296 | Pediatric Solid... | - 25 Years | St. Jude Children's Research Hospital | ||
| Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma | NCT01883518 | Sarcoma Neoplasms, Conn... | Autologous dend... | 18 Years - | N.N. Petrov National Medical Research Center of Oncology | |
| Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas | NCT03054792 | Rhabdomyosarcom... Non-Rhabdo. Sof... | 18F-FAZA (F18-F... Blood Oxygen Le... Diffusion-Weigh... Magnetic Resona... | 6 Years - 18 Years | The Hospital for Sick Children | |
| Radiation Therapy to Treat Musculoskeletal Tumors | NCT00186992 | Sarcoma, Ewing'... Rhabdomyosarcom... Soft Tissue Sar... Musculoskeletal... | image-guided ra... | - 25 Years | St. Jude Children's Research Hospital | |
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | NCT02536183 | Pediatric Cance... Solid Tumors Rhabdomyosarcom... Ewing Sarcoma Soft Tissue Sar... Osteosarcoma Neuroblastoma Wilms Tumor Hepatic Tumor Germ Cell Tumor... | Magnetic resona... Lyso-thermosens... | - 30 Years | Children's National Research Institute | |
| Indocyanine Green (ICG) Guided Tumor Resection | NCT04084067 | Neoplastic Dise... Solid Tumor | Indocyanine Gre... | - | St. Jude Children's Research Hospital | |
| Evolutionary Therapy for Rhabdomyosarcoma | NCT04388839 | Rhabdomyosarcom... | Vincristine Cyclophosphamid... Vinorelbine Actinomycin D Cyclophosphamid... | - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | NCT04906876 | Sarcoma Soft Tissue Sar... Metastatic Sarc... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma | Gemcitabine Docetaxel 9-ING-41 | 10 Years - | Brown University | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | NCT05116800 | Soft Tissue Sar... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma Osteosarcoma Ewing Sarcoma o... | Gemcitabine 9-ING-41 Docetaxel | 10 Years - | Brown University | |
| Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma | NCT00919269 | Adult Rhabdomyo... Childhood Desmo... Chordoma Desmoid-Type Fi... Metastatic Chil... Non-Metastatic ... Previously Trea... Recurrent Adult... Recurrent Child... Recurrent Child... Rhabdomyosarcom... Stage I Adult S... Stage II Adult ... Stage III Adult... Stage IV Adult ... Untreated Child... | Cytology Specim... Laboratory Biom... | - 50 Years | Children's Oncology Group | |
| Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | NCT01674101 | Osteosarcoma Ewing's Sarcoma Rhabdomyosarcom... Synovial Sarcom... Malignant Perip... Malignant Fibro... Chondrosarcoma ... | Endurance Strengthening Stretching Home exercise p... | 6 Years - 30 Years | St. Jude Children's Research Hospital | |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | NCT02013336 | Recurrent or Re... Ewing Sarcoma Rhabdomyosarcom... Neuroblastoma Osteosarcoma | MM-398 (Irinote... | 12 Months - 20 Years | South Plains Oncology Consortium | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Proton RT for the Treatment of Pediatric Rhabdomyosarcoma | NCT00592592 | Rhabdomyosarcom... | Proton Beam Rad... | - 21 Years | Massachusetts General Hospital | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | NCT03458728 | Relapsed or Ref... Neuroblastoma Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma | Copanlisib (BAY... | 6 Months - 21 Years | Bayer | |
| Molecular Analysis Of Solid Tumors | NCT01050296 | Pediatric Solid... | - 25 Years | St. Jude Children's Research Hospital | ||
| A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | NCT00001564 | Ewing's Sarcoma Rhabdomyosarcom... | EF-1 Peptide EF-2 Peptide PXFK Peptide E7 Peptide IL-2 IL-4 GM-CSF CD40 Ligand | - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | NCT02624388 | Lymphoma Childhood Lymph... Solid Tumor Childhood Solid... Neuroblastoma Ewing Sarcoma Hodgkin Lymphom... Non-Hodgkin Lym... Rhabdomyosarcom... Soft Tissue Sar... Medulloblastoma Germ Cell Tumor Wilms Tumor Brain Neoplasms Medulloblastoma... Neuroectodermal... | Genistein Placebo | 1 Year - 21 Years | University of Virginia | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | NCT00931931 | Rhabdomyosarcom... Osteosarcoma Ewing Sarcoma Soft Tissue Sar... Neuroblastoma Wilms Tumor Malignant Perip... Clival Chordoma Non-CNS Solid T... | HSV1716 | 7 Years - 30 Years | Nationwide Children's Hospital | |
| Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma | NCT05457829 | Rhabdomyosarcom... | Doxorubicin Hyd... Temozolomide+Ir... | 6 Months - 18 Years | Sun Yat-sen University | |
| Indocyanine Green (ICG) Guided Tumor Resection | NCT04084067 | Neoplastic Dise... Solid Tumor | Indocyanine Gre... | - | St. Jude Children's Research Hospital | |
| Tabectedin to Treat Children and Adolescents With Cancer | NCT01453283 | Solid Tumors | Trabectedin (ec... | 4 Years - 16 Years | National Institutes of Health Clinical Center (CC) | |
| Trabectedin and Irinotecan for Refractory Pediatric Sarcomas | NCT02509234 | Recurrent Child... Recurrent Ewing... Recurrent Rhabd... | Combined chemot... | 10 Years - 40 Years | Technical University of Munich | |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | NCT04995003 | Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate... | T cells or CAR ... Pembrolizumab I... Nivolumab Injec... | 1 Year - 25 Years | Baylor College of Medicine | |
| A Study of Pemetrexed in Children With Recurrent Cancer | NCT00520936 | Osteosarcoma Medulloblastoma Sarcoma, Ewing'... Neuroblastoma (... Neuroblastoma (... Positive Evalua... Rhabdomyosarcom... Ependymoma Non-brainstem H... | pemetrexed | - 22 Years | Eli Lilly and Company | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | NCT00001335 | Ewing's Sarcoma Neuroblastoma Rhabdomyosarcom... | ADR-529 Topotecan G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | NCT02890758 | Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Non Hodgkin Lym... Hodgkin Lymphom... Myeloproliferat... Plasma Cell Mye... Colon Carcinoma Adenocarcinoma ... Soft Tissue Sar... Ewing's Sarcoma Rhabdomyosarcom... | Natural Killer ... ALT803 | 18 Years - | Case Comprehensive Cancer Center | |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | NCT05302921 | Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Relapsed Pediat... Refractory Pedi... Melanoma Hepatoblastoma Hepatocellular ... Neuroblastoma Wilms Tumor | Cryoablation Th... Nivolumab Ipilimumab | 1 Year - 39 Years | Children's National Research Institute | |
| A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | NCT05135975 | Neuroblastoma Sarcoma | Cabozantinib | 18 Months - 40 Years | Nationwide Children's Hospital | |
| Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | NCT04299113 | Rhabdomyosarcom... | Vinorelbine Mocetinostat | 13 Years - | Jonsson Comprehensive Cancer Center | |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | NCT02574728 | Cancer | Sirolimus Celecoxib Etoposide Cyclophosphamid... | 12 Months - 30 Years | Emory University | |
| Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | NCT02945800 | Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Soft Tissue Sar... | nab-Paclitaxel Gemcitabine | 3 Years - 30 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | NCT03507491 | Cancer | Gemcitabine Nab-paclitaxel | 6 Months - 30 Years | Emory University | |
| Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | NCT00187109 | Germ Cell Tumor... Hepatic Cancer Neuroblastoma Osteosarcoma Rhabdomyosarcom... | Recombinant Hum... | - 21 Years | St. Jude Children's Research Hospital | |
| Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas | NCT03054792 | Rhabdomyosarcom... Non-Rhabdo. Sof... | 18F-FAZA (F18-F... Blood Oxygen Le... Diffusion-Weigh... Magnetic Resona... | 6 Years - 18 Years | The Hospital for Sick Children | |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | NCT04995003 | Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate... | T cells or CAR ... Pembrolizumab I... Nivolumab Injec... | 1 Year - 25 Years | Baylor College of Medicine | |
| Blood and Tissue Study of Patients in NIH Protocol 08-C-0800 | NCT00923325 | Sarcomas | 2 Years - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
